2-(bis(2-methoxyethyl)amino)-1-ethanol | 155796-28-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(bis(2-methoxyethyl)amino)-1-ethanol
• 英文别名: 2-[Bis(2-methoxyethyl)amino]ethanol
• CAS: 155796-28-4
• 化学式: C₈H₁₉NO₃
• 分子量: 177.244
• InChiKey: YLPUPVLGIIAANM-UHFFFAOYSA-N

物化性质

• 保留指数：
  1291

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(bis(2-methoxyethyl)amino)-1-ethanol 在 盐酸 、 氯化亚砜 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 苯 为溶剂， 反应 4.0h， 生成 1-{[2-bis(2-methoxyethyl)amino]ethyl}-1,3-cyclopentadiene
  参考文献：
  名称：

  Internally Solvated Cyclopentadienyllithium Compounds:  Structural Integrity of the Cp^-Li⁺ Moiety. NMR, Dynamics, X-ray Crystallography, and Calculations

  摘要：

  Three cyclopentadienyllithium compounds with the tethered, T, ligand -N(CH2CH2OCH3)(2) are as follows: T = CHCH(CH3)(2),6; T = (CH2)(2), 10; T = (CH2)(3),14. The results of NOE NMR experiments for 6, 10, and 14 together with X-ray crystallography of 14 support internally coordinated monomeric structures for all three compounds. Models have been constructed for 6, 10, and 14 from modifications of an internally solvated allylic lithium compound at the B3LYP level of theory using basis set 6-311G*. The resulting structural features are very similar to those obtained from the NMR and crystallographic data. In addition, C-13 NMR shifts obtained with the GIAO procedure using the results of the B3LYP/6-311G* calculations are closely similar to the experimental shifts, which validate B3LYP as a suitable model for these compounds. The Li+ centroid distance of ca. 1.9 angstrom to 2.0 angstrom obtained for 6, 10, and 14 is common to most crystallographic data for externally solvated Cp-Li+ compounds as well as one which incorporates a (CpLiCp)(-) triple ion. It is concluded that the ligand tether and the stereochemistry around Li+ accommodate to maintain the structural integrity of Cp-Li+. NMR and crystallography show 14 to be chiral. Carbon-13 NMR line shape changes are attributed to inversion via a lateral wobble mechanism with Delta H-double dagger = 6 kcal(.)mol(-1) and Delta S-double dagger = -2 eu. It is also shown that a 6,6-dimethylfulvene is deprotonated at methyl by LiN(CH2-CH2OCH3)(3) as well as by butyllithium in the presence of PMDTA producing isopropenyl Cp-Li+ compounds 24 and 25, respectively. NMR line shape changes of the sample containing 24 have been qualitatively interpreted to result from a combination of fast transfer of coordinated ligand between faces of the carbanion plane as well as a lithium-exchange process.

  DOI：

  10.1021/jo0512507
• 作为产物：
  描述：

  2-氯乙醇 、 双(2-甲氧基乙基)胺 在 potassium carbonate 作用下， 以 苯 为溶剂， 反应 24.0h， 以88%的产率得到2-(bis(2-methoxyethyl)amino)-1-ethanol
  参考文献：
  名称：

  Internally Solvated Cyclopentadienyllithium Compounds:  Structural Integrity of the Cp^-Li⁺ Moiety. NMR, Dynamics, X-ray Crystallography, and Calculations

  摘要：

  Three cyclopentadienyllithium compounds with the tethered, T, ligand -N(CH2CH2OCH3)(2) are as follows: T = CHCH(CH3)(2),6; T = (CH2)(2), 10; T = (CH2)(3),14. The results of NOE NMR experiments for 6, 10, and 14 together with X-ray crystallography of 14 support internally coordinated monomeric structures for all three compounds. Models have been constructed for 6, 10, and 14 from modifications of an internally solvated allylic lithium compound at the B3LYP level of theory using basis set 6-311G*. The resulting structural features are very similar to those obtained from the NMR and crystallographic data. In addition, C-13 NMR shifts obtained with the GIAO procedure using the results of the B3LYP/6-311G* calculations are closely similar to the experimental shifts, which validate B3LYP as a suitable model for these compounds. The Li+ centroid distance of ca. 1.9 angstrom to 2.0 angstrom obtained for 6, 10, and 14 is common to most crystallographic data for externally solvated Cp-Li+ compounds as well as one which incorporates a (CpLiCp)(-) triple ion. It is concluded that the ligand tether and the stereochemistry around Li+ accommodate to maintain the structural integrity of Cp-Li+. NMR and crystallography show 14 to be chiral. Carbon-13 NMR line shape changes are attributed to inversion via a lateral wobble mechanism with Delta H-double dagger = 6 kcal(.)mol(-1) and Delta S-double dagger = -2 eu. It is also shown that a 6,6-dimethylfulvene is deprotonated at methyl by LiN(CH2-CH2OCH3)(3) as well as by butyllithium in the presence of PMDTA producing isopropenyl Cp-Li+ compounds 24 and 25, respectively. NMR line shape changes of the sample containing 24 have been qualitatively interpreted to result from a combination of fast transfer of coordinated ligand between faces of the carbanion plane as well as a lithium-exchange process.

  DOI：

  10.1021/jo0512507

文献信息

• [EN] NUCLEIC ACID CHEMICAL MODIFICATIONS<br/>[FR] MODIFICATIONS CHIMIQUES D'ACIDE NUCLÉIQUE
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2010101951A1

  公开（公告）日：2010-09-10

  he present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

  本发明提供了式（1）的核苷和包含至少一种式（2）核苷的寡核苷酸；发明的另一个方面涉及一种抑制细胞中基因表达的方法，该方法包括（a）将本发明的寡核苷酸与细胞接触；和（b）维持步骤（a）中的细胞足够长的时间以获得目标基因mRNA的降解。
• Novel quinazolines and uses thereof
  申请人：——

  公开号：US20030100573A1

  公开（公告）日：2003-05-29

  This invention relates to compounds of the general formula: 1 in which R A , R B , R C and R D are as defined herein, and to their preparation and use.

  这项发明涉及一般式为1的化合物，其中RA、RB、RC和RD的定义如本文所述，以及它们的制备和用途。
• [EN] HETEROCYCLES AND USES THEREOF<br/>[FR] HETEROCYCLES ET LEURS UTILISATIONS
  申请人：ARIAD PHARMA INC

  公开号：WO2004058267A1

  公开（公告）日：2004-07-15

  Compounds of the following formula are disclosed: wherein RB is a substituted or unsubstituted aryl or heteroaryl moiety; at least one of RU and RL is a phosphorus-containing moiety, J, and the other of RU and RL is independently chosen from H; halogen; -CN; -N02; -J; -SO2R; -S02NRR'; or -ZRJ, wherein each occurrence of Z is independently -0-, -S- or -NR- and each occurrence of RJ is independently -R, -COR, -COOR or -CONRR.

  本发明披露了以下式子的化合物：其中RB是取代或未取代的芳基或杂环芳基基团；RU和RL中至少一个是含磷基团的基团J，而另一个是独立选择的H；卤素；-CN；-N02；-J；-SO2R；-S02NRR'或-ZRJ，其中Z的每次出现独立地是-0-，-S-或-NR-，而RJ的每次出现独立地是-R，-COR，-COOR或CONRR。
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ZENECA LIMITED

  公开号：WO1996033980A1

  公开（公告）日：1996-10-31

  (EN) The invention concerns quinazoline derivatives of the formula (I) wherein n is 1, 2 or 3 and each R2 is independently halogeno, trifluoromethyl or (1-4C)alkyl; R3 is (1-4C)alkoxy; and R1 is di-[(1-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy, 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy, imidazol-1-yl-(2-4C)alkoxy, di-[(1-4C)alkoxy-(2-4C)alkoxyl]amino-(2-4C)alkoxy, thiamorpholino-(2-4C)alkoxy, 1-oxothiamorpholino-(2-4C)alkoxy or 1,1-dioxothiamorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R1 substituents comprising a CH2 (methylene) group which is not attached to a N or O atom optionally bears on said CH2 group a hydroxy substituent; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.(FR) L'invention concerne des dérivés de quinazoline de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci. Dans la formule (I), n vaut 1, 2 ou 3 et chaque R2 représente séparément halogéno, trifluorométhyle ou alkyle (1-4C); R3 représente alcoxy (1-4C); et R1 représente di[alkyl(1-4C)]amino-alcoxy(2-4C), pyrrolidin-1-yl-alcoxy(2-4C), pipéridino-alcoxy(2-4C), morpholino-alcoxy(2-4C), pipérazin-1-yl-alcoxy(2-4C), 4-alkylpipérazin(1-4C)-1-yl-alcoxy(2-4C), imidazol-1-yl-alcoxy(2-4C), di[alcoxy(1-4C)-alkyl(2-4C)]amino-alcoxy(2-4C), thiamorpholino-alcoxy(2-4C), 1-oxothiamorpholino-alcoxy(2-4C) ou 1,1-dioxothiamorpholino-alcoxy(2-4C), et dans laquelle les substituants de R1 susmentionnés comprenant un groupe CH¿2(méthylène) qui n'est pas attaché à un atome N ou O porte éventuellement sur ledit groupe CH2 un substituant hydroxy. L'invention porte aussi sur des procédés de préparation desdits composés, des compositions pharmaceutiques les contenant et l'utilisation des propriétés inhibitrices de la tyrosine-kinase réceptrice du composé dans le traitement de maladies prolifératives telles que le cancer.

  本发明涉及式(I)的喹唑啉衍生物，其中n为1、2或3，每个R2独立地为卤素、三氟甲基或(1-4C)烷基；R3为(1-4C)烷氧基；R1为双[(1-4C)烷基]氨基-(2-4C)烷氧基、吡咯烷-1-基-(2-4C)烷氧基、哌啶-(2-4C)烷氧基、吗啉-(2-4C)烷氧基、哌嗪-1-基-(2-4C)烷氧基、4-(1-4C)烷基哌嗪-1-基-(2-4C)烷氧基、咪唑-1-基-(2-4C)烷氧基、双[(1-4C)烷氧基-(2-4C)烷氧基]氨基-(2-4C)烷氧基、硫代吗啉-(2-4C)烷氧基、1-氧代硫代吗啉-(2-4C)烷氧基或1,1-二氧代硫代吗啉-(2-4C)烷氧基，其中上述任何一个具有未连接到N或O原子的CH2(亚甲基)基的R1取代基可选择在该 基上具有一个羟基取代基；或其药学上可接受的盐；以及它们的制备方法、包含它们的制药组合物和利用该化合物的受体酪氨酸激酶抑制性质治疗增殖性疾病如癌症的用途。
• [EN] ANILINE DERIVATIVES<br/>[FR] DERIVES DE L'ANILINE
  申请人：ZENECA LIMITED

  公开号：WO1996015118A1

  公开（公告）日：1996-05-23

  (EN) The invention concerns aniline derivatives of formula (I) wherein m is 1, 2 or 3 and each R1 includes halogeno, hydroxy, amino, hydroxyamino, ureido, trifluoromethoxy and (1-4C)alkyl; n is 0, 1, 2 or 3 and each R2 includes halogeno, trifluoromethyl, hydroxy, amino, nitro, cyano and (1-4C)alkyl; X is a group of the formula CO, C(R3)2, CH(OR3), C(R3)2-C(R3)2, C(R3)=C(R3), C=C, CH(CN), O, S, SO, SO2, CONR3, SO2NR3, NR3CO, NR3SO2, OC(R3)2, SC(R3)2, C(R3)2O or C(R3)2S wherein each R3 is independently hydrogen or (1-4C)alkyl; and Q is a phenyl or naphthyl group or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.(FR) L'invention concerne des dérivés de l'aniline de la formule (I). Dans cette formule, m vaut 1, 2 ou 3 et chaque R1 représente halogéno, hydroxy, amino, hydroxyamino, uréido, trifluorométhoxy et (1-4C) alkyle; n vaut 0, 1, 2 ou 3 et chaque R2 représente halogéno, trifluorométhyle, hydroxy, amino, nitro, cyano et (1-4C) alkyle; X est un groupe de la formule CO, C(R3)2, CH(OR3), C(R3)2-C(R3)2, C(R3)=C(R3), C=C, CH(CH), O, S, SO, SO2, CONR3, SO2NR3, NR3CO, NR3CO2, OC(R3)2, SC(R3)2, C(R3)2O ou C(R3)2S, où chaque R3 est indépendamment hydrogène ou (1-4C) alkyle; et Q est un groupe de phényle ou de naphthyle ou une fraction hétéroarylique à 5 ou 6 éléments comprenant 1, 2 ou 3 hétéroatomes choisis parmi l'oxygène, l'azote et le soufre. L'invention concerne également un sel de la présente formule qui soit acceptable sur le plan pharmaceutique; des procédés pour leur préparation, des compositions pharmaceutiques à base de ces substances, et l'utilisation des propriétés inhibitrices du récepteur de tyrosine-kinase des composés dans le traitement de maladies à évolution chronique telles que le cancer.

  本发明涉及公式（I）的苯胺衍生物，其中m为1、2或3，每个R1包括卤素、羟基、氨基、羟氨基、脲基、三氟甲氧基和（1-4C）烷基；n为0、1、2或3，每个R2包括卤素、三氟甲基、羟基、氨基、硝基、氰基和（1-4C）烷基；X是公式CO、C（R3）2、CH（OR3）、C（R3）2-C（R3）2、C（R3）=C（R3）、C=C、CH（CN）、O、S、SO、SO2、CONR3、SO2NR3、NR3CO、NR3SO2、OC（R3）2、SC（R3）2、C（R3）2O或C（R3）2S的基团，其中每个R3独立地为氢或（1-4C）烷基；Q是苯基或萘基或包含1、2或3个氧、氮和硫杂原子的5或6元杂环基；或其药学上可接受的盐；制备它们的方法，含有它们的制药组合物，以及利用化合物的受体酪氨酸激酶抑制性质治疗增殖性疾病，如癌症。